TSA v RSA in Osteoarthritic Shoulders With Greater Than 15 Degrees of Retroversion

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorOttawa Hospital Research Institute

About this trial

This study will compare total shoulder arthroplasty (TSA) with an augmented glenoid component and reverse shoulder arthroplasty (RSA) procedures, in participants with advanced glenohumeral osteoarthritis aged 65 years and older, who also present with greater than 15 degrees of glenoid retroversion, in the context of a prospective, randomized controlled trial to determine the optimal treatment in this patient population.

Eligibility criteria

Qualifiers

Diagnosis of idiopathic shoulder OA.

Patients who have failed standard non-surgical management of their shoulder OA who would benefit from a shoulder arthroplasty. Failed medical management will be defined as persistent pain and disability despite adequate standard non-operative management for at least 6 months. Medical management will be defined as: a) The use of drugs including analgesics and nonsteroidal anti-inflammatory drugs, b) Physiotherapy consisting of stretching, strengthening and local modalities (ultrasound, cryotherapy, etc.), c) Activity modification

Imaging, and intra-operative findings confirming advanced glenohumeral cartilage loss

Patients with a glenoid deficiency and >15 degrees of glenoid retroversion up to a maximum of 26 degrees of glenoid retroversion (i.e. -15.1, -17, -20…etc.)

Disqualifiers

Active joint or systemic infection

Rotator cuff arthropathy

Significant muscle paralysis

Charcot's arthropathy

Trial design

Treatments tested in this trial

  • Total Shoulder Arthroplasty + augmented glenoid component
  • Reverse Shoulder Arthroplasty

Treatment groups

108 Participants
are divided into 2 treatment groups